How many drug targets are there?

Nature Reviews Drug Discovery

Volumn 5, Issue 12, 2006, Pages 993-996

  Overington, John P ^a   Al Lazikani, Bissan ^a   Hopkins, Andrew L ^b  

^a Inpharmatica Ltd   (United Kingdom)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACEBUTOLOL; ALPHA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR; CARVEDILOL; CETIRIZINE; CETUXIMAB; CYTOCHROME P450 3A4; ERLOTINIB; FLT3 LIGAND; GEFITINIB; HISTAMINE H1 RECEPTOR; HYDROXYZINE; IMATINIB; LOPINAVIR; PANITUMUMAB; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PRODRUG; PROTEIN KINASE; PROTEINASE INHIBITOR; RAF PROTEIN; RITONAVIR; SORAFENIB; SUNITINIB; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

ARTICLE; CONSENSUS; DRUG ABSORPTION; DRUG APPROVAL; DRUG TARGETING; HUMAN; HUMAN GENOME; MULTIGENE FAMILY; NONHUMAN; PHARMACOLOGICAL BLOCKING; POLYPHARMACY; PRIORITY JOURNAL; PROTEIN TARGETING;

DRUG APPROVAL; DRUG DELIVERY SYSTEMS; DRUG DESIGN; DRUGS, INVESTIGATIONAL; GENOME, HUMAN; HUMANS; TECHNOLOGY, PHARMACEUTICAL;

EID: 33751547539     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd2199     Document Type: Article

References (27)

1. Drews, J. Genomic sciences and the medicine of tomorrow. Nature Biotechnol. 14, 1516-1518 (1996).
2. Drews, J. & Ryser, S. Classic drug targets. Nature Biotechnol. 15, 1318-1319 (1997).
3. Lipinski, C. A., Lombardo, F., Dominy, B. W. & Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Del. Rev. 23, 3-25 (1997).
4. Hopkins, A. L. & Groom, C. R. The druggable genome. Nature Rev. Drug Discov. 1, 727-730 (2002).
5. Golden, J. B. Prioritizing the human genome: Knowledge management for drug discovery. Curr. Opin. Drug Discov. Dev. 6, 310-316 (2003).
6. Golden, J. Towards a tractable genome: Knowledge management in drug discovery. Curr. Drug Discov. 17-20 (2003).
7. Wishart, D. S. et al. DrugBank: A comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Res. 43, D668-D672 (2006).
8. Imming, P., Sinning, C. & Meyer, A. Drugs, their targets and the nature and number of drug targets. Nature Rev. Drug Discov. 5, 821-834 (2006).
9. Zheng, C., Han, L., Yap, C. W., Xie, B. & Chen, Y. Progress and problems in the exploration of therapeutic targets. Drug Discov. Today 11, 412-420 (2006).
10. Zheng, C. J. et al. Therapeutic targets: Progress of their explorations and investigation of their characteristics. Pharma. Rev. 58, 259-279 (2006).
11. Druker, B. J. et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nature Med. 2, 561-566 (1996).
12. Fabian, M. A. et al. A small molecule-kinase interaction map for clinical kinase inhibitors. Nature Biotechnol. 23, 329-336 (2005).
13. Atwell, S. et al. A novel mode of Gleevec binding is revealed by the structure of spleen tyrosine kinase. J. Biol. Chem. 279, 55827-55832 (2004).
14. Heinrich, M. C. et al. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 96, 925-932 (2000).
15. Ahmad, T. & Eisen, T. Kinase inhibition with BAY 43-9006 in renal cell carcinoma. Clin. Cancer Res. 10, 6388S-6392S (2004).
16. Weber, A. et al. Unexpected nanomolar inhibition of carbonic anhydrase by COX-2-selective celecoxib: New pharmacological opportunities due to related binding site recognition. J. Med. Chem. 47, 550-557 (2004).
17. Paolini, G. V., Shapland, R. H. B., van Hoorn, W. P., Mason, J. S. & Hopkins, A. L. Global mapping of pharmacological space. Nature Biotechnol. 24, 805-815 (2006).
18. Hopkins, A. L., Mason, J. S. & Overington, J. P. Can we rationally design promiscuous drugs?. Curr. Opin. Struct. Biol. 16, 127-136 (2006).
19. Murzin, A. G., Brenner, S. E., Hubbard, T. & Chothia, C. SCOP: A structural classification of proteins database for the investigation of sequences and structures. J. Mol. Biol. 274, 536-540 (1995).
20. Bateman, A. et al. The Pfam Protein Families Database. Nucleic Acids Res. 32, D138-D141 (2004).
21. Koonin, E. V., Wolf, Y. I. & Karev, G. P. The structure of the protein universe and genome evolution. Nature 420, 218-223 (2002).
22. Vitkup, D., Melamud, E., Moult, J. & Sander, C. Completeness in structural genomics. Nature Struct. Biol. 8, 559-566 (2001).
23. Berman, H. M. et al. The Protein Data Bank. Nucleic Acid Res. 28, 235-242 (2000).
24. McKusick, V. A. in Mendelian Inheritance in Man 12th Edn (John Hopkins University Press, Baltimore, 1998).
25. NIHCM 24 pp (National Institute for Health Care Management Research and Educational Foundation, 2002).
26. Christensen, C. M. The Innovator's Dilemma: When New Technologies Cause Great Firms to Fail (Harvard Business School Press, Cambridge, 1997).
27. Raju, T. N. The Nobel chronicles. Lancet 355, 1022 (2000).